"Missed Out on Vaccine Gold Rush?" Part 2

Presuming the BusinessInsider.com report is correct, then CureVac's stock may bounce around in the current trading range. As we get closer to the August EMA meeting, I'd expect the stock to move higher again in anticipation of approval.